Revenue, 2025

USD 1.43 Billion

Forecast, 2035

USD 4.19 Billion

CAGR, 2026-2035

11.22%

Report Coverage

Asia Pacific

Key Takeaways of APAC Central Lab Market

• APAC central lab market to crossed USD 1.61 billion by 2026.
• Market projected at USD 4.19 billion by 2035.
• CAGR of 11.22% expected in between 2026 to 2035.
• The global central lab market is set to grow from USD 7.17 billion in 2026 to USD 15.78 billion by 2035 at a 9.16% CAGR, driven by R&D and clinical trial demand.
• China dominated the APAC central lab market in 2025, with a 31.58% share.
• India held an 11.62% share of the market in 2025 and is expected to grow at the fastest CAGR of 12.41% during the forecast period.
• By service type, the safety testing segment led the market with a 35.41% share in 2025.
• By service type, the genomic & molecular testing segment held a 17.06% share in 2025 and is expected to grow at the fastest rate of 13.47% during the forecast period.
• By therapeutic area, the oncology segment held a 33.38% share in 2025.
• By therapeutic area, the rare diseases & genetic disorders segment captured a 4.74% share in 2025 and is expected to be the fastest-growing segment with a CAGR of 15.73% during the forecast period.
• By clinical trial phase, the phase III segment led the market with a 54.50% share in 2025.
• By clinical trial phase, the phase IV segment captured a 16.92% share in 2025 and is expected to grow at the highest CAGR of 12.77% during 2026-2035.
• By modality, the biologics segment dominated the market with a revenue of 41.13% in 2025.
• By modality, the advanced therapies (ATMP) segment held a 14.76% share in 2025 and is expected to grow at the fastest CAGR of 15.97% during the forecast period.
• By end-user, the pharmaceutical & biotechnology companies segment dominated the APAC central lab market in 2025, with a revenue share of 62.51%.
• By end-user, the contract research organizations (CROs) segment captured a 16.16% share in 2025 and is expected to grow at the fastest CAGR of 12.45% during the forecast period.

APAC Central Lab Market Trends for 2026

The APAC central lab market size was estimated at US$ 1.43 billion in 2025, projected to increase to US$ 1.61 billion in 2026 and reach US$ 4.19 billion by 2035, showing a healthy CAGR of 11.22% across the forecast years.

The APAC central lab market is expanding rapidly due to increasing adoption of advanced diagnostic technologies, rising awareness of precision medicine, and growing demand for efficient clinical trial support. The region benefits from cost-effective laboratory services, rising pharmaceutical R&D, and expanding collaborations between local labs and global CROs. Additionally, technological innovations, enhanced sample management capabilities, and increasing regulatory compliance initiatives are driving the market’s growth, making APAC a significant contributor to the global central lab sector.

What is APAC Central Lab?

The APAC central lab market is growing due to rising clinical trials, expanding pharmaceutical R&D, and increasing adoption of advanced laboratory and diagnostic technologies across the region. The market comprises centralized laboratory facilities providing comprehensive services to support clinical trials, research, and diagnostic testing across. These labs offer services such as genetic testing, biomarker analysis, microbiology, anatomic pathology, and specimen management to pharmaceutical, biotechnology, and healthcare organizations.

Driven by rising healthcare investments, increasing clinical trial activities, and the adoption of precision diagnostics, the APAC central lab market is witnessing significant growth and technological advancement, enabling improved efficiency, data accuracy, and regulatory compliance across the region.

APAC Central Lab Market Outlook

• Industry Growth Overview- The market is growing steadily, driven by increasing clinical trials, expanding pharmaceutical research, adoption of advanced lab technologies, rising outsourcing, and government support for healthcare infrastructure and diagnostics.
• Global Expansion- The market seeks global growth by strengthening cross-border partnerships, increasing capacity for multinational clinical trials, integrating innovative diagnostic solutions, and positioning the region as a reliable hub for high-quality laboratory services.
• Major Investors- Key investors in the APAC central lab market include regional biotech firms, multinational pharmaceutical companies, healthcare technology providers, and strategic investment funds supporting expansion of laboratory networks, innovative testing services, and clinical trial capabilities.

How Can AI Affect the Market?

AI is transforming the APAC central lab market by enabling intelligent sample management, automated reporting, and enhanced pattern recognition for complex datasets. It facilitates faster clinical trial analyses, improves operational efficiency, and reduces costs. Additionally, AI supports advanced predictive modeling, multi-omics data interpretation, and quality control, helping labs meet regulatory standards while accelerating research and drug development. This integration strengthens lab capabilities, enhances service scalability, and positions APAC as a competitive hub for innovative central laboratory solutions.

What are the Key Trends in the APAC Central Lab Market in 2025?

• Expansion of Pharmaceutical and Biotech R&D- Growth in pharmaceutical and biotechnology research in the region fuels demand for specialized laboratory services, biomarker testing, and analytical support.
• In September 2025, LyondellBasell will upgrade its Suzhou Technical Center in China with a new extrusion line and processing workshop, enhancing compounding for complex polypropylene and engineered plastics, and enabling faster, innovative solutions for automotive, electronics, and consumer goods.
• Innovation in Laboratory Technologies- Adoption of advanced testing methods, automation, and high-throughput technologies improves accuracy, efficiency, and scalability of lab services across clinical trials.
• In July 2025, Carbon Clean opened its Global Innovation Centre in Navi Mumbai, India, featuring carbon capture plants and advanced labs. The facility accelerates research and deployment of CycloneCC, its modular, cost-effective carbon capture technology.

Key Indicators and Highlights

Segmental Insights

Service Type Insights

The Safety Testing Segment Led the Market in 2025

The safety testing segment led the APAC central lab market with a 35.41% share in 2025, driven by stringent regulatory requirements for drug development, increasing clinical trial activity, and growing emphasis on patient safety monitoring. Pharmaceutical and biotechnology companies increasingly rely on centralized laboratory services for toxicology, pharmacokinetic, and adverse event assessments, ensuring standardized data quality, regulatory compliance, and efficient decision-making across multicenter studies throughout Asia-Pacific.

The genomic & molecular testing segment held a 17.06% share in 2025 and is expected to grow at the fastest rate of 13.47% during the forecast period, supported by rising adoption of precision medicine, expanding oncology research, and increasing demand for biomarker-based diagnostics. Advances in sequencing technologies, declining testing costs, and greater integration of genetic insights into clinical trials continue to accelerate segment expansion across APAC markets.

The pathology & histology services segment captured a revenue share of the APAC central lab market of 16.22% in 2025 due to its critical role in disease diagnosis, tissue analysis, and therapeutic evaluation during clinical studies. The growing prevalence of cancer and chronic diseases has increased demand for accurate specimen examination. Central laboratories offered standardized workflows, expert interpretation, and high-quality reporting, enabling researchers and sponsors to obtain reliable data for regulatory and treatment decisions.

The specialty testing & biomarkers segment captured a revenue share of 14.41% in 2025, fueled by increasing use of targeted therapies, personalized treatment approaches, and advanced clinical research programs. Biomarker testing supports patient stratification, treatment response monitoring, and early disease detection, making it essential in modern drug development. Rising investments in translational research and precision healthcare further strengthened demand for specialized laboratory testing services.

Therapeutic Area Insights

The Oncology Segment Dominated the Market in 2025

The oncology segment held a 33.38% share of the APAC central lab market in 2025, driven by the rising cancer burden, increasing clinical trial activity, and growing adoption of precision medicine. Central laboratories supported biomarker analysis, genomic testing, and treatment monitoring, enabling standardized, high-quality data generation across multicenter oncology studies.

The infectious diseases segment captured a revenue share of 19.32% in 2025 due to persistent concerns regarding emerging pathogens, antimicrobial resistance, and outbreak preparedness. Growing demand for diagnostic testing, surveillance programs, and vaccine-related clinical research has increased reliance on central laboratories for accurate, standardized, and timely testing services across APAC.

The cardiovascular & metabolic diseases (CVMD) segment captured a revenue share of the APAC central lab market of 18.46% in 2025, supported by the increasing prevalence of heart disease, diabetes, and obesity across APAC. Central laboratories played a vital role in biomarker testing, patient monitoring, and clinical trial support, ensuring reliable data for therapeutic development.

The rare diseases & genetic disorders segment captured a 4.74% share in 2025 and is expected to be the fastest-growing segment with a CAGR of 15.73% during the forecast period, driven by advances in genetic testing, increasing orphan drug development, and expanding precision medicine initiatives. Greater awareness and research investments are further accelerating segment growth.

Clinical Trial Phase Insights

The Phase III Segment Dominated the Market in 2025

The phase III segment led the APAC central lab market with a 54.50% share in 2025, owing to the large patient populations, extensive testing requirements, and high volume of multicenter clinical trials conducted during this stage. Central laboratories ensured standardized sample analysis, regulatory compliance, and data consistency, supporting the validation of drug efficacy and safety before regulatory approval.

The phase I & II segment captured a revenue share of 28.58% in 2025, driven by increasing early-stage drug development activities and growing investments in clinical research. Central laboratories provided essential services, including biomarker testing, pharmacokinetic assessments, and safety evaluations, enabling sponsors to generate reliable data and accelerate candidate progression through development pipelines.

The phase IV segment captured a 16.92% share in 2025 and is expected to grow at the highest CAGR of 12.77% during 2026-2035, supported by increasing emphasis on post-marketing surveillance and real-world evidence generation. Rising requirements for long-term safety monitoring, treatment effectiveness assessments, and regulatory compliance are driving demand for central laboratory services.

Modality Insights

The Biologics Segment Led the Market in 2025

The biologics segment dominated the APAC central lab market with a revenue of 41.13% in 2025, driven by increasing development of monoclonal antibodies, recombinant proteins, and cell-based therapies. Biologics require complex analytical testing, immunogenicity assessments, and biomarker evaluation, increasing reliance on central laboratories to ensure regulatory compliance, data accuracy, and efficient clinical trial execution.

The small molecules segment captured a revenue share of 34.43% in 2025 due to the continued prevalence of conventional drug development programs across therapeutic areas. Central laboratories supported pharmacokinetic studies, safety testing, and bioanalytical services, enabling sponsors to generate reliable clinical data while maintaining regulatory standards and accelerating development timelines throughout the region.

The advanced therapies (ATMP) segment held a 14.76% share in 2025 and is expected to grow at the fastest CAGR of 15.97% in the APAC central lab market during the forecast period, supported by rising investments in gene therapies, cell therapies, and regenerative medicine. These therapies require specialized laboratory testing and complex analytical workflows, driving increasing demand for centralized expertise and advanced clinical trial support services.

The vaccines segment captured a revenue share of 9.68% in 2025, supported by ongoing immunization initiatives, infectious disease research, and expanding vaccine development programs. Central laboratories played a key role in serology testing, immune response monitoring, and safety assessments, helping sponsors generate standardized data and meet regulatory requirements across multicenter clinical studies.

End-User Insights

The Pharmaceutical & Biotechnology Companies Segment Led the Market

The pharmaceutical & biotechnology companies segment dominated the APAC central lab market in 2025, with a revenue share of 62.51%, driven by substantial investments in drug development, increasing clinical trial activity, and growing demand for outsourced laboratory services. Central laboratories supported these organizations with standardized testing, regulatory-compliant data generation, and efficient sample management, helping accelerate product development and commercialization efforts.

The contract research organizations (CROs) segment captured a 16.16% share in 2025 and is expected to grow at the fastest CAGR of 12.45% during the forecast period. Rising outsourcing trends, increasing complexity of clinical studies, and demand for cost-effective research solutions are encouraging CROs to expand their service offerings, driving greater utilization of centralized laboratory testing capabilities.

The academic & government research institutes segment captured a revenue share of the APAC central lab market of 13.75% in 2025, supported by growing public research funding, collaborative clinical studies, and increasing focus on disease surveillance and healthcare innovation. Central laboratories provided advanced testing infrastructure, specialized analytical capabilities, and standardized processes, enabling researchers to conduct high-quality studies and generate reliable scientific evidence.

The clinical diagnostic laboratories segment captured a revenue share of 7.59% in 2025 due to its role in supporting routine testing, disease diagnosis, and patient monitoring activities. Growing demand for accurate laboratory results, expanding healthcare access, and increasing adoption of advanced diagnostic technologies contributed to the segment’s steady utilization of central laboratory services across the region.

Regional Insights

What are the Factors Supporting Market Growth in the Asia Pacific?

How is China contributing to the Expansion of the APAC Central Lab Market?

China dominated the APAC central lab market in 2025, with a revenue of 31.58% China is driving Market growth with the revenue shares, by emerging as a hub for specialized and high-throughput laboratory services. Increasing private sector investments, expansion of independent and reference laboratories, and integration of digital and automated lab technologies are boosting efficiency. Furthermore, partnerships with international pharmaceutical companies and CROs for multi-site clinical trials, along with growing focus on precision medicine and biomarker research, are strengthening China’s role as a key contributor to the region’s central lab market expansion.

India Market Trends

India held an 11.62% share of the APAC central lab market in 2025 and is expected to grow at the fastest CAGR of 12.41% during the forecast period. India is fueling the APAC Central Lab Market’s expansion by emerging as a preferred destination for outsourced laboratory services and multi-site clinical trials. The country’s growing network of independent and hospital-based laboratories, increasing adoption of automated and high-throughput testing technologies, and rising focus on biomarker and genomic research are driving market growth. Strategic collaborations with global pharmaceutical companies and CROs, along with ongoing infrastructure development, further strengthen India’s role in the region’s central lab ecosystem.

Japan Market Trends

Japan captured a significant APAC central lab market share of 15.58% in 2025. Japan’s APAC Central Lab Market is expanding as the country focuses on innovative drug development and regenerative medicine research. Rising investment in laboratory automation, high-throughput testing, and genomic analysis enhances service capabilities. Additionally, Japan’s emphasis on regulatory compliance, collaborations with international pharmaceutical companies, and growing participation in multinational clinical trials are driving demand for centralized lab services, positioning the country as a key contributor to APAC’s overall central laboratory market growth.

Global Central Lab Market Growth

The global central lab market is valued at USD 7.17 billion in 2026 and is projected to reach USD 15.78 billion by 2035, growing at a CAGR of 9.16% from 2026 to 2035, driven by increasing investments in R&D and a growing demand for clinical trials.

Market Ecosystem Analysis

APAC Central Lab Market Value Chain Analysis

Clinical Trial

• Clinical trials using an APAC central lab involve sending samples to a centralized lab in the Asia-Pacific region for standardized, high-quality testing.
• This ensures consistent, accurate, and comparable data across all trial sites.
• APAC is becoming a key hub for clinical research due to large patient populations and a growing number of trials.
• Compliance with global standards like GCP makes the region a preferred choice for central lab services in international studies.

Serialization

• Serialization in APAC central labs involves tracking and managing clinical trial materials to prevent counterfeit medicines.
• The process is complex due to diverse national regulations across the region.
• Unlike the standardized rules in the U.S. or EU, APAC requires a flexible, multi-level approach to comply with developed, emerging, and loosely regulated markets.
• Effective serialization ensures safety, compliance, and integrity of clinical trial supplies across the region.

Patient Support and Services

• In APAC, patient support services for central labs focus on clinical trial management and diagnostic testing.
• Services follow a collaborative model involving laboratories, CROs, healthcare providers, and technology platforms.
• The approach emphasizes supporting trials and diagnostics rather than direct-to-patient care.

Top Vendors and their Offerings

• Thermo Fisher Scientific- Thermo Fisher Scientific provides comprehensive laboratory solutions, including analytical testing, central lab services, genomic and molecular diagnostics, sample management, and clinical trial support, enabling pharmaceutical, biotech, and healthcare organizations to advance research efficiently.
• IQVIA- IQVIA provides end-to-end life sciences solutions, including laboratory testing, biomarker analysis, data management, and technology-enabled clinical trial support, helping pharmaceutical and biotech companies accelerate research, ensure compliance, and improve patient outcomes worldwide.
• ICON plc- ICON plc delivers specialized laboratory and clinical trial services, including sample processing, advanced diagnostics, regulatory compliance support, and integrated study management, enabling pharmaceutical and biotech companies to conduct efficient, high-quality global research programs.
• Labcorp- Labcorp delivers end-to-end clinical research solutions, offering specialized testing, pharmacology studies, patient sample logistics, and data management services, helping pharmaceutical and biotech companies optimize drug development and streamline global trial operations.
• Quest Diagnostics- Quest Diagnostics offers specialized laboratory solutions, including high-throughput testing, biomarker analysis, sample management, and clinical research support, enabling pharmaceutical, biotech, and healthcare organizations to accelerate studies and maintain regulatory compliance globally.

Top Companies in the APAC Central Lab Market

• Charles River Laboratories
• Medpace
• Frontage Laboratories
• SGS S.A.
• Eurofins Scientific
• REPROCELL Inc.
• ACM Global Laboratories
• LabConnect
• Cerba Research
• Synevo Central Labs
• Versiti
• Cenetron
• Ampersand Capital Partners
• Pacific Biomarkers
• Cirion BioPharma Research

Market Share Influence Assessment

Competitive Landscape

SWOT Analysis

Strengths

• Lower Operational Costs: Facilities in hubs like India and China across APAC offer highly cost-effective labor and infrastructure compared to Western regions, maximizing R&D budgets.
• Large, Diverse Patient Pool: The massive and genetically diverse population, which enables faster recruitment for clinical trials and provides robust, highly representative testing data.

Weaknesses

• Workforce Shortages: A critical deficit of licensed psychiatrists, psychologists, and specialized therapists limits access to care.
• High Out-of-Pocket Costs: Insurance mandates, deductibles, and out-of-pocket costs for specialized or out-of-network behavioral care remain prohibitively high for many.

Opportunities

• Surge in Genetic & Biomarker Services: Genetic services and biomarker services are the fastest-growing and highest-revenue segments, heavily fueled by oncology and rare disease research.
• Pharma Nearshoring: Global biopharmaceutical companies are increasingly outsourcing clinical trials to APAC, moving operations closer to these massive patient populations to reduce costs.

Threats

• Geopolitical & Trade Uncertainties: Shifting trade policies and geopolitical tensions can disrupt the supply chain for essential laboratory reagents and analytical equipment.
• Strict Local Regulations: Emerging data privacy and cross-border data-sharing restrictions can complicate the centralization of clinical trial results.

Recent Developments in the APAC Central Lab Market

• In March 2025, IQVIA Laboratories launched Site Lab Navigator, a solution designed to automate and optimize lab workflows for clinical trial sponsors and investigator sites. The platform features an e-Requisition system, enabling electronic submission of lab requests and streamlined management of specimens.

Segments Covered in the Report

By Service Type

• Safety Testing
  
  • Hematology
  • Clinical Chemistry (Metabolic Panels, Urinalysis)
  • Coagulation & Liver Function Testing
• Specialty Testing & Biomarkers
  
  • Biomarker Services
  • Flow Cytometry
  • Multiplex Assays
• Genomic & Molecular Testing
  
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence in Situ Hybridization (FISH)
  • Gene Expression Profiling
• Pathology & Histology Services
  
  • Anatomic Pathology
  • Cytopathology
  • Immunohistochemistry (IHC)
• Microbiology & Virology
  
  • Pathogen Surveillance
  • Viral Load Monitoring
• Clinical Supply Chain & Biorepository
  
  • Specimen Management
  • Kit Preparation
  • Logistics & Cold Chain Management
  • Cryopreservation
    

By Therapeutic Area

• Oncology
  • Immuno-oncology
  • Hematological Malignancies
• Infectious Diseases
  
  • Virological Research (HIV, COVID-19, Hepatitis)
  • Bacterial & Fungal Infections
  • Tropical & Emerging Diseases
• Cardiovascular & Metabolic Diseases (CVMD)
  
  • Diabetes
  • Obesity
  • Heart Failure
• Neurology & Central Nervous System (CNS)
  • Alzheimer’s & Dementia
  • Multiple Sclerosis
  • Rare Neurological Disorders
• Immunology & Autoimmune Diseases
  
  • Rheumatoid Arthritis
  • Psoriasis & Inflammatory Bowel Disease (IBD)
• Rare Diseases & Genetic Disorders

By Clinical Trial Phase

• Phase I & II (Early Phase)
• Phase III (Late Phase)
• Phase IV (Post-Marketing Surveillance)

By Modality

• Small Molecules
• Biologics (Large Molecules)
  
  • Monoclonal Antibodies
  • Recombinant Proteins
• Advanced Therapies (ATMP)
  
  • Cell Therapy
  • Gene Therapy
• Vaccines

By End-User

• Pharmaceutical & Biotechnology Companies
  
  • Large Cap Pharma
  • Emerging Biotech
• Contract Research Organizations (CROs)
• Academic & Government Research Institutes
• Clinical Diagnostic Laboratories

By Region

• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand